Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

ConditionObesity

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorSecond Xiangya Hospital of Central South University

About this trial

To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.

This trial does not accept healthy volunteers

Aged 18-60 years, regardless of sex/gender

BMI≥28.0kg/m2

Aged 18-60 years, regardless of sex/gender

BMI≥24.0kg/m2

Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes

Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections

Use of weight-affecting products within the past three months or planned use during the study

Weight fluctuation >5 kg or >10% within the past three months

Design model

Parallel

Attapulgite
Dietary supplement
Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.
Placebo
Dietary supplement
Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.

40 Participants

are divided into 2 treatment groups

Group A: AttapulgiteExperimental treatment 1 intervention

Group B: PlaceboPlacebo comparator 1 intervention

BMI (Body Mass Index)

BMI used to assess body weight relative to height, the unit of BMI is kg/m² (kilograms per square meter).

Time frame